Актуальные вопросы ведения пациентов с диабетической полинейропатией
Актуальные вопросы ведения пациентов с диабетической полинейропатией
Храмилин В.Н. Актуальные вопросы ведения пациентов с диабетической полинейропатией. Consilium Medicum. 2016; 18 (9): 110–115. DOI: 10.26442/2075-1753_2016.9.110-115
________________________________________________
Khramilin V.N. Topical issues of managing the diabetic polyneuropathy patients. Consilium Medicum. 2016; 18 (9): 110–115. DOI: 10.26442/2075-1753_2016.9.110-115
Актуальные вопросы ведения пациентов с диабетической полинейропатией
Храмилин В.Н. Актуальные вопросы ведения пациентов с диабетической полинейропатией. Consilium Medicum. 2016; 18 (9): 110–115. DOI: 10.26442/2075-1753_2016.9.110-115
________________________________________________
Khramilin V.N. Topical issues of managing the diabetic polyneuropathy patients. Consilium Medicum. 2016; 18 (9): 110–115. DOI: 10.26442/2075-1753_2016.9.110-115
Диабетическая полинейропатия и нейропатическая боль в значительной мере ухудшают качество жизни пациентов с сахарным диабетом. Клиническая гетерогенность пациентов с диабетической полинейропатией может рассматриваться как основа алгоритмов лечения и дифференцированного выбора лекарственных препаратов.
Diabetic neuropathy and neuropathic pain worsen the quality of life of patients with diabetes. Clinical heterogeneity diabetic polyneuropathy can be considered as the basis of algorithms and differential choice of treatment strategy.
1. Бреговский В.Б., Храмилин В.Н., Демидова И.Ю. и др. Диабетическая дистальная полинейропатия. Обзор современных рекомендаций. Анналы неврологии. 2015; 9 (1): 60–8. / Bregovskii V.B., Khramilin V.N., Demidova I.Iu., Strokov I.A., Gur'eva I.V. Diabeticheskaia distal'naia polineiropatiia. Obzor sovremennykh rekomendatsii. Annaly nevrologii. 2015; 9 (1): 60–8. [in Russian]
2. Дедов И.И., Омельяновский В.В., Шестакова М.В. и др. Cахарный диабет как экономическая проблема в Российской Федерации. Сахарный диабет. 2016; 19 (1): 30–43. / Dedov I.I., Omel'ianovskii V.V., Shestakova M.V. i dr. Cakharnyi diabet kak ekonomicheskaia problema v Rossiiskoi Federatsii. Sakharnyi diabet. 2016; 19 (1): 30–43. [in Russian]
3. Дедов И.И., Шестакова М.В. Результаты реализации подпрограммы «Сахарный диабет» федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007–2012 годы». Сахарный диабет. Спецвыпуск. 2013. / Dedov I.I., Shestakova M.V. Rezul'taty realizatsii podprogrammy “Sakharnyi diabet” federal'noi tselevoi programmy “Preduprezhdenie i bor'ba s sotsial'no znachimymi zabolevaniiami 2007–2012 gody”. Sakharnyi diabet. Spetsvypusk. 2013. [in Russian]
4. Сунцов Ю.И., Дедов И.И., Шестакова М.В. Скрининг осложнений сахарного диабета как метод оценки качества лечебной помощи больным. М., 2008. / Suntsov Iu.I., Dedov I.I., Shestakova M.V. Skrining oslozhnenii sakharnogo diabeta kak metod otsenki kachestva lechebnoi pomoshchi bol'nym. M., 2008. [in Russian]
5. Храмилин В.Н., Андреева В.А., Демидова И.Ю. Комбинированная терапия диабетической полинейропатии: результаты пилотного исследования. Фарматека. 2014; 16 (289): 48–53. / Khramilin V.N., Andreeva V.A., Demidova I.Iu. Kombinirovannaia terapiia diabeticheskoi polineiropatii: rezul'taty pilotnogo issledovaniia. Farmateka. 2014; 16 (289): 48–53. [in Russian]
6. Хуторная О.Е. Частота выявления различных форм диабетической полинейропатии нижних конечностей в популяции больных сахарным диабетом в Санкт-Петербурге и подходы к ее лечению. Автореф. дис. ... канд. мед. наук. СПб: ФМИЦ, 2013. / Khutornaia O.E. Chastota vyiavleniia razlichnykh form diabeticheskoi polineiropatii nizhnikh konechnostei v populiatsii bol'nykh sakharnym diabetom v Sankt-Peterburge i podkhody k ee lecheniiu. Avtoref. dis. ... kand. med. nauk. SPb: FMITs, 2013. [in Russian]
7. Abbott CA, Malik RA et al. Prevalence and Characteristics of Painful Diabetic Neuropathy in a Large Community-Based Diabetic Population in the U.K. Diabet Care 2011; 34 (10): 2220–4.
8. Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD007543. DOI: 10.1002/14651858.CD007543.pub2.
9. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. The Cochrane Library 2012, Issue 7. DOI: 10.1002/14651858.CD008943.pub2
10. Davies M, Brophy S, Williams R, Taylor A. The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes. Diabet Care 2006; 29: 1518–22.
11. DCCT (The Diabetes Control and Complications Trial Research Group). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
12. DCCT Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Int Med 1995; 122: 561–8.
13. Fedele D, Comi G, Coscelli C et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Diabet Care 1997; 20 (5): 836–43.
14. Finnerup NB, Attal N et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015: 162–73.
15. Fisher TZ, Waxman SG. Neuropathic pain in diabetes-evidence for a central mechanism. Nature Rev Neurology 2010; 6: 462–6.
16. Franklin GM, Kahn LB, Baxter J et al. Sensory neuropathy in noninsulin-dependent diabetes mellitus. Am J Epidemiol 1990; 131: 633–43.
17. Franklin GM, Shetterly SM, Cohen JA et al. Risk factors for distal symmetric neuropathy in NIDDM. Diabet Care 1994; 17: 1172–7.
18. Fraser DA, Diep LM, Hovden IA et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabet Care 2012; 35 (5): 1095–7.
19. Hartemann A, Attal N, Bouhassira D et al. Painful diabetic neuropathy: diagnosis and management. Diabet Metab 2011; 37 (5): 377–88.
20. Haupt E, Ledermann H, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005; 43 (2): 71–7.
21. International diabetes federation, diabetes atlas, seventh edition, 2013. Available at http://www.diabetesatlas.org/.
22. Jacobs AM, Cheng D. Addition of Metanx in pregabalin partial responders for painful diabetic neuropathy. J Diabetes Mellitus 2013; 3 (3): 134–8.
23. Man-chun Wong, Chung JWY. Chapter 14 in Erin Lawson, Miroslav Backonja. Painful Diabetic Polyneuropathy. A Comprehensive Guide for Clinicians. DOI 10.1007/978-1-4614-6299-6 . Springer New York Heidelberg Dordrecht London. 2013.
24. Manes Ch, Papazoglou N et al. Prevalence of Diabetic Neuropathy and Foot Ulceration: Identification of Potential Risk Factors – A Population-Based Study. Wounds 2002; 14 (1): 11–5.
25. Maser RE, Steenkiste AR, Dorman JS et al. Epidemiological correlates of diabetic neuropathy: report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989; 38: 1456–61.
26. Medina-Santillán R, Morales-Franco G, Espinoza-Raya J et al. Treatment of Diabetic Neuropathic Pain with Gabapentin Alone or Combined with Vitamin B Complex. Preliminary Results. Proc West Pharmacol Soc 2004; 47: 109–12.
27. Pfiefer MA, Schumer MP. Clinical trials of diabetic neuropathy: Past, present and future. Diabetes 1995; 44: 1355–61.
28. Singleton RJ, Smith AG, Marcus RL. Exercise as Therapy for Diabetic and Prediabetic Neuropathy. Curr Diab Rep 2015; 15: 120.
29. Sorensen L, Molyneaux L, Yue DK. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. Diabetes Res Clin Pract 2002; 57: 45–51.
30. Stracke H, Gaus W, Achenbach U et al. Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a Randomised, Double Blind, Placebo-controlled Clinical Study. Exp Clin Endocrinol Diabetes 2008; 116 (10): 600–5.
31. Tesfaye S, Stevens LK, Stephenson JM et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1377–84.
32. Tesfaye S et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care 2010; 33: 2285–93.
33. Tesfaye S, Selvarajahb D, Gandhi R et al. Diabetic peripheral neuropathy may not be as its name suggests evidence from magnetic resonance imaging. Pain 2016; 157: S72–S80.
34. Young MJ, Boulton AJM, MacLeod AF et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150–4.
35. Ziegler D et al. Diabetic Neuropathy. German Diabetes Association: Clinical Practice Guidelines. Exp Clin Endocrinol Diabetes 2014; 122: 406–15.
36. Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy: DiaCAN Multicenter Study Group. Diabet Med 1993; 10 (Suppl. 2): 82S– 86S.
37. Ziegler D et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011; 34 (9): 2054–60.
38. Ziegler D. Painful Diabetic Neuropathy. Advantage of novel drugs over old drugs? Diabetes Care 2009; 32 (Suppl. 2): S414–419.
39. Ziegler D, Schneider E, Boess FG et al. Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice. J Diabet Complic 2015; 28: 698–704.
________________________________________________
1. Bregovskii V.B., Khramilin V.N., Demidova I.Iu., Strokov I.A., Gur'eva I.V. Diabeticheskaia distal'naia polineiropatiia. Obzor sovremennykh rekomendatsii. Annaly nevrologii. 2015; 9 (1): 60–8. [in Russian]
2. Dedov I.I., Omel'ianovskii V.V., Shestakova M.V. i dr. Cakharnyi diabet kak ekonomicheskaia problema v Rossiiskoi Federatsii. Sakharnyi diabet. 2016; 19 (1): 30–43. [in Russian]
3. Dedov I.I., Shestakova M.V. Rezul'taty realizatsii podprogrammy “Sakharnyi diabet” federal'noi tselevoi programmy “Preduprezhdenie i bor'ba s sotsial'no znachimymi zabolevaniiami 2007–2012 gody”. Sakharnyi diabet. Spetsvypusk. 2013. [in Russian]
4. Suntsov Iu.I., Dedov I.I., Shestakova M.V. Skrining oslozhnenii sakharnogo diabeta kak metod otsenki kachestva lechebnoi pomoshchi bol'nym. M., 2008. [in Russian]
5. Khramilin V.N., Andreeva V.A., Demidova I.Iu. Kombinirovannaia terapiia diabeticheskoi polineiropatii: rezul'taty pilotnogo issledovaniia. Farmateka. 2014; 16 (289): 48–53. [in Russian]
6. Khutornaia O.E. Chastota vyiavleniia razlichnykh form diabeticheskoi polineiropatii nizhnikh konechnostei v populiatsii bol'nykh sakharnym diabetom v Sankt-Peterburge i podkhody k ee lecheniiu. Avtoref. dis. ... kand. med. nauk. SPb: FMITs, 2013. [in Russian]
7. Abbott CA, Malik RA et al. Prevalence and Characteristics of Painful Diabetic Neuropathy in a Large Community-Based Diabetic Population in the U.K. Diabet Care 2011; 34 (10): 2220–4.
8. Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD007543. DOI: 10.1002/14651858.CD007543.pub2.
9. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. The Cochrane Library 2012, Issue 7. DOI: 10.1002/14651858.CD008943.pub2
10. Davies M, Brophy S, Williams R, Taylor A. The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes. Diabet Care 2006; 29: 1518–22.
11. DCCT (The Diabetes Control and Complications Trial Research Group). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
12. DCCT Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Int Med 1995; 122: 561–8.
13. Fedele D, Comi G, Coscelli C et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Diabet Care 1997; 20 (5): 836–43.
14. Finnerup NB, Attal N et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015: 162–73.
15. Fisher TZ, Waxman SG. Neuropathic pain in diabetes-evidence for a central mechanism. Nature Rev Neurology 2010; 6: 462–6.
16. Franklin GM, Kahn LB, Baxter J et al. Sensory neuropathy in noninsulin-dependent diabetes mellitus. Am J Epidemiol 1990; 131: 633–43.
17. Franklin GM, Shetterly SM, Cohen JA et al. Risk factors for distal symmetric neuropathy in NIDDM. Diabet Care 1994; 17: 1172–7.
18. Fraser DA, Diep LM, Hovden IA et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabet Care 2012; 35 (5): 1095–7.
19. Hartemann A, Attal N, Bouhassira D et al. Painful diabetic neuropathy: diagnosis and management. Diabet Metab 2011; 37 (5): 377–88.
20. Haupt E, Ledermann H, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005; 43 (2): 71–7.
21. International diabetes federation, diabetes atlas, seventh edition, 2013. Available at http://www.diabetesatlas.org/.
22. Jacobs AM, Cheng D. Addition of Metanx in pregabalin partial responders for painful diabetic neuropathy. J Diabetes Mellitus 2013; 3 (3): 134–8.
23. Man-chun Wong, Chung JWY. Chapter 14 in Erin Lawson, Miroslav Backonja. Painful Diabetic Polyneuropathy. A Comprehensive Guide for Clinicians. DOI 10.1007/978-1-4614-6299-6 . Springer New York Heidelberg Dordrecht London. 2013.
24. Manes Ch, Papazoglou N et al. Prevalence of Diabetic Neuropathy and Foot Ulceration: Identification of Potential Risk Factors – A Population-Based Study. Wounds 2002; 14 (1): 11–5.
25. Maser RE, Steenkiste AR, Dorman JS et al. Epidemiological correlates of diabetic neuropathy: report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989; 38: 1456–61.
26. Medina-Santillán R, Morales-Franco G, Espinoza-Raya J et al. Treatment of Diabetic Neuropathic Pain with Gabapentin Alone or Combined with Vitamin B Complex. Preliminary Results. Proc West Pharmacol Soc 2004; 47: 109–12.
27. Pfiefer MA, Schumer MP. Clinical trials of diabetic neuropathy: Past, present and future. Diabetes 1995; 44: 1355–61.
28. Singleton RJ, Smith AG, Marcus RL. Exercise as Therapy for Diabetic and Prediabetic Neuropathy. Curr Diab Rep 2015; 15: 120.
29. Sorensen L, Molyneaux L, Yue DK. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. Diabetes Res Clin Pract 2002; 57: 45–51.
30. Stracke H, Gaus W, Achenbach U et al. Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a Randomised, Double Blind, Placebo-controlled Clinical Study. Exp Clin Endocrinol Diabetes 2008; 116 (10): 600–5.
31. Tesfaye S, Stevens LK, Stephenson JM et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1377–84.
32. Tesfaye S et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care 2010; 33: 2285–93.
33. Tesfaye S, Selvarajahb D, Gandhi R et al. Diabetic peripheral neuropathy may not be as its name suggests evidence from magnetic resonance imaging. Pain 2016; 157: S72–S80.
34. Young MJ, Boulton AJM, MacLeod AF et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150–4.
35. Ziegler D et al. Diabetic Neuropathy. German Diabetes Association: Clinical Practice Guidelines. Exp Clin Endocrinol Diabetes 2014; 122: 406–15.
36. Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy: DiaCAN Multicenter Study Group. Diabet Med 1993; 10 (Suppl. 2): 82S– 86S.
37. Ziegler D et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011; 34 (9): 2054–60.
38. Ziegler D. Painful Diabetic Neuropathy. Advantage of novel drugs over old drugs? Diabetes Care 2009; 32 (Suppl. 2): S414–419.
39. Ziegler D, Schneider E, Boess FG et al. Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice. J Diabet Complic 2015; 28: 698–704.
Авторы
В.Н.Храмилин
ФГБОУ ВО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1 Khramilin_RGMU@mail.ru
________________________________________________
V.N.Khramilin
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1 Khramilin_RGMU@mail.ru